Shares of BioMarin Pharmaceutical (BMRN) slipped in premarket trading on Tuesday after the company announced plans to discontinue the development of its dwarfism therapy Voxzogo for Noonan syndrome, a rare genetically driven developmental disorder.

According to a federal register on